BioCentury | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

NIH pitches policy for greater sharing of data NIH has published a draft of the NIH Policy for Data Management and Sharing to promote wider sharing of data and results generated from NIH-funded grant work...
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...
BioCentury | Nov 3, 2014
Financial News

DCPrime completes venture financing

DCPrime B.V. , Amsterdam, the Netherlands Business: Cancer Date completed: 2014-10-28 Type: Venture financing Raised: Not disclosed Investor: SkylineDx B.V. Note: The amount raised is not disclosed. WIR Staff cancer...
BioCentury | Oct 7, 2013
Company News

DCPrime, J&J deal

Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary received rights to use DCPrime's DCOne technology in feasibility studies to develop a dendritic cell-based vaccine. The biotech's DCOne technology is based on its human dendritic cell line...
BioCentury | Oct 5, 2013
Company News

J&J in trio of European deals

Johnson & Johnson (NYSE:JNJ) announced three deals, including a deal in which Effimune S.A.S . (Nantes, France) granted J&J an exclusive option to FR104 , a human mAb CD28 antagonist in preclinical development for autoimmune diseases. Effimune...
BioCentury | Jun 17, 2013
Clinical News

DCP-001: Phase I/II data

An open-label, dose-escalation, Dutch Phase I/IIa trial in 12 elderly patients at high risk of relapse who were ineligible for post-remission therapy showed that DCP-001 given every 2 weeks for 4 vaccinations was safe and...
BioCentury | Oct 15, 2012
Company News

DCPrime management update

DCPrime B.V. , Amsterdam, the Netherlands Business: Cancer Appointed: Anthony Hall as CMO, formerly CMO of PSR Group B.V. Promoted: Marcel Zwaal to CEO from CBO; he replaces Ada Kruisbeek, who remains CSO WIR Staff cancer...
BioCentury | Jul 2, 2012
Clinical News

DCP-001 regulatory update

The European Commission granted Orphan Drug designation for DCPrime's DCP-001 to treat acute myelogenous leukemia (AML). The off-the-shelf dendritic cell vaccine based on the company's DCOne technology is in Phase I/IIa testing for the indication....
BioCentury | Jun 18, 2012
Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
BioCentury | Feb 6, 2012
Clinical News

DCP-001 regulatory update

EMA's CHMP issued a positive opinion to grant Orphan Drug designation for DCPrime's DCP-001 to treat acute myelogenous leukemia (AML). The off-the-shelf dendritic cell vaccine based on the company's DCOne technology is in Phase I/IIa...
Items per page:
1 - 10 of 12
BioCentury | Nov 8, 2019
Preclinical News

Nov. 7 Preclinical Quick Takes: NIH drafts policy requiring more data sharing; plus Unum, Mission-BioLegend, DCprime and more

NIH pitches policy for greater sharing of data NIH has published a draft of the NIH Policy for Data Management and Sharing to promote wider sharing of data and results generated from NIH-funded grant work...
BioCentury | Nov 8, 2019
Finance

Van Herk’s DCprime ready to boost its cell-based cancer vaccine

With a steady stream of small investments from the Van Herk Group, DCprime is now poised to raise its next financing from a broader group of investors to expand the Dutch cancer vaccine company’s product...
BioCentury | Nov 3, 2014
Financial News

DCPrime completes venture financing

DCPrime B.V. , Amsterdam, the Netherlands Business: Cancer Date completed: 2014-10-28 Type: Venture financing Raised: Not disclosed Investor: SkylineDx B.V. Note: The amount raised is not disclosed. WIR Staff cancer...
BioCentury | Oct 7, 2013
Company News

DCPrime, J&J deal

Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary received rights to use DCPrime's DCOne technology in feasibility studies to develop a dendritic cell-based vaccine. The biotech's DCOne technology is based on its human dendritic cell line...
BioCentury | Oct 5, 2013
Company News

J&J in trio of European deals

Johnson & Johnson (NYSE:JNJ) announced three deals, including a deal in which Effimune S.A.S . (Nantes, France) granted J&J an exclusive option to FR104 , a human mAb CD28 antagonist in preclinical development for autoimmune diseases. Effimune...
BioCentury | Jun 17, 2013
Clinical News

DCP-001: Phase I/II data

An open-label, dose-escalation, Dutch Phase I/IIa trial in 12 elderly patients at high risk of relapse who were ineligible for post-remission therapy showed that DCP-001 given every 2 weeks for 4 vaccinations was safe and...
BioCentury | Oct 15, 2012
Company News

DCPrime management update

DCPrime B.V. , Amsterdam, the Netherlands Business: Cancer Appointed: Anthony Hall as CMO, formerly CMO of PSR Group B.V. Promoted: Marcel Zwaal to CEO from CBO; he replaces Ada Kruisbeek, who remains CSO WIR Staff cancer...
BioCentury | Jul 2, 2012
Clinical News

DCP-001 regulatory update

The European Commission granted Orphan Drug designation for DCPrime's DCP-001 to treat acute myelogenous leukemia (AML). The off-the-shelf dendritic cell vaccine based on the company's DCOne technology is in Phase I/IIa testing for the indication....
BioCentury | Jun 18, 2012
Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
BioCentury | Feb 6, 2012
Clinical News

DCP-001 regulatory update

EMA's CHMP issued a positive opinion to grant Orphan Drug designation for DCPrime's DCP-001 to treat acute myelogenous leukemia (AML). The off-the-shelf dendritic cell vaccine based on the company's DCOne technology is in Phase I/IIa...
Items per page:
1 - 10 of 12